Related Experiment Video
Updated: Jul 1, 2026
09:36
Assessment of Child Anthropometry in a Large Epidemiologic Study
Published on: February 2, 2017
Obesity in the pediatric headache population: a multicenter study.
Andrew D Hershey1, Scott W Powers, Timothy D Nelson
1Cincinnati Children's Hospital Medical Center-Neurology, Cincinnati, OH 45229, USA.
Headache
|September 12, 2008
Summary
Pediatric obesity is linked to more frequent and disabling headaches. Weight loss in overweight children can reduce headache frequency over time, highlighting the importance of weight management in pediatric headache care.
Area of Science:
- Pediatric neurology
- Obesity research
- Public health
Background:
- Headache and obesity are prevalent in children and adults.
- Adult studies suggest a link between headache and obesity.
- This relationship is under-explored in pediatric populations.
Purpose of the Study:
- Examine pediatric obesity prevalence.
- Correlate weight with headache frequency and disability.
- Assess weight change impact on pediatric headache outcomes.
Main Methods:
- Collected data on 913 pediatric patients across 7 centers.
- Measured height, weight, age, gender, headache frequency, and disability.
- Calculated Body Mass Index (BMI) percentile and tracked changes at 3- and 6-month follow-ups.
Main Results:
- Overweight prevalence in the cohort matched the general pediatric population.
- BMI percentile correlated with initial headache frequency and disability.
- In obese/overweight children, BMI change positively correlated with headache frequency change at follow-up.
Conclusions:
- Childhood obesity is associated with increased headache frequency and disability.
- Weight loss in overweight children can lead to reduced headaches.
- Clinicians should consider patient weight status when managing pediatric headaches.
Related Concept Videos
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...